Emergent BioSolutions, Inc.
400 Professional Drive
About Emergent BioSolutions, Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia.
399 articles with Emergent BioSolutions, Inc.
Although bioterrorism doesn’t get the kind of attention more traditional bombings and shootings receive, the biotech industry and the federal government are paying attention and actively funding and developing countermeasures to potential bioterror, military and public health emergencies.
Politicians might deny climate change, but disease-carrying insects and their pathogens aren’t—they’re exploiting it.
Touting that it is helping fight the opioid epidemic, Emergent BioSolutions is acquiring Adapt Pharma. Under the terms of the deal, Emergent will pay $635 million up front and up to $100 million in cash for various sales-based milestones through 2022.
CEPI Awards Contract Worth up to $36 Million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus Vaccine
CEPI (the Coalition for Epidemic Preparedness Innovations) today announced a new collaboration with Profectus BioSciences, Inc. and Emergent BioSolutions Inc. (NYSE: EBS) under which they will receive up to USD $36 million to advance the development and manufacture of a vaccine against the Lassa virus—an estimated 100,000 to 300,000 cases of Lassa virus infection occur each year.1
8/15/2018On a dollar-for-dollar basis, vaccines have probably had a greater positive effect on global health than any other medical advancement, except possibly antibiotics. Yet as a whole, it’s an area that pharma companies tend to not spend a lot of resources on. But there are still many companies that ...
Emergent BioSolutions, headquartered in Gaithersburg, Maryland, inked a deal to buy PaxVax, based in Redwood City, California, for $270 million in cash.
Combined company will capitalize on PaxVax's robust pipeline, proven commercial track record, and validated scientific and clinical acumen
ZIKV-IG granted Fast Track designation by the U.S. Food and Drug Administration
Emergent BioSolutions to Release Fourth Quarter and Full Year 2017 Financial Results and Conduct a Conference Call on February 22, 2018
This conference call can be accessed live by telephone or by webcast.
Emergent BioSolutions Announces Preliminary 2017 Financial Results and Provides 2018 Financial Outlook
For the full year 2017, the company anticipates total revenue of $555 to $560 million, the midpoint of which represents a $69 million or 14% increase from 2016.
Emergent BioSolutions Initiates Phase II Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection
This Phase 2 clinical study will enroll approximately 75 adult patients hospitalized with serious illness caused by influenza A infection in up to 50 sites within the U.S.
Emergent BioSolutions Awarded Department of National Defence Contract to Supply Anthrasil to the Canadian Government
This contract award follows the recent approval of Anthrasil by Health Canada under the Extraordinary Use New Drug (EUND) Regulations.
This event, which is designed for sellside research analysts and institutional investors, will take place at The Westin New York at Times Square, 270 West 43rd Street, New York, New York 10036.
Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility
ACAM2000 is the only FDA-licensed vaccine for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection.
Emergent BioSolutions Announces Notice of Termination of Conversion Rights of 2.875% Convertible Senior Notes Due 2021
As of November 13, 2017, approximately $250 million aggregate principal amount of the Notes were outstanding.
Emergent BioSolutions Reports Third Quarter and Nine Months 2017 Financial Results; Raises Calendar Year 2017 Guidance
For Q3 2017, Total revenues were $149.4 million, an increase of 5% as compared to 2016.
Emergent BioSolutions to Release Third Quarter and Nine Months 2017 Financial Results and Conduct a Conference Call on November 2, 2017
The company will also host a conference call at 5:00 pm (Eastern Time) at which time members of management will discuss these results.
Emergent BioSolutions Awarded U.S. Department Of State Contract Valued At Up To $25 Million To Supply Nerve Agent Antidote Auto-Injector
Emergent BioSolutions Completes Acquisition Of Raxibacumab, An FDA-Approved Anthrax Monoclonal Antibody, From GlaxoSmithKline